Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sharps Technology Inc. Warrant (STSSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: STSSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -37.5% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 219876 | Beta 1.46 | 52 Weeks Range 0.01 - 0.21 | Updated Date 02/25/2025 |
52 Weeks Range 0.01 - 0.21 | Updated Date 02/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.43% | Return on Equity (TTM) -92.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1787152 |
Shares Outstanding - | Shares Floating 1787152 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sharps Technology Inc. Warrant
Company Overview
History and Background
Sharps Technology, Inc. focuses on developing and manufacturing injectable drug delivery systems. The warrant gives the holder the right to purchase shares of Sharps Technology Inc. common stock under specified conditions.
Core Business Areas
- Drug Delivery Systems: Development and manufacture of safety syringe products and other injectable devices.
Leadership and Structure
Information on leadership team and organizational structure can be found on the company's website and investor relations materials.
Top Products and Market Share
Key Offerings
- Safety Syringes: Sharps Technology's primary product is a line of safety syringes designed to prevent needlestick injuries. The market share information requires proprietary research and isn't publicly available. Competitors include Becton Dickinson, Smiths Medical, and Terumo.
Market Dynamics
Industry Overview
The injectable drug delivery market is driven by factors such as increasing demand for biologics, growing prevalence of chronic diseases, and a focus on patient safety.
Positioning
Sharps Technology aims to differentiate itself through its safety syringe technology. Competitive advantages would rely on proprietary technology and cost-effectiveness.
Total Addressable Market (TAM)
TAM for injectable drug delivery systems is estimated to be in the billions of dollars globally. Sharps Technology's positioning within this TAM depends on its market penetration and product adoption.
Upturn SWOT Analysis
Strengths
- Proprietary safety syringe technology
- Focus on preventing needlestick injuries
- Potential to capitalize on increasing safety regulations
Weaknesses
- Limited market presence compared to larger competitors
- Dependence on single product line
- Financial stability is a major concern for investors.
Opportunities
- Expanding into new markets
- Developing new injectable drug delivery systems
- Partnering with pharmaceutical companies
Threats
- Competition from established players
- Regulatory changes
- Product recalls or safety concerns
Competitors and Market Share
Key Competitors
- BDX
- SMTH
- TRMO
Competitive Landscape
Sharps Technology faces significant competition from larger, more established players in the medical device industry. Its success depends on its ability to innovate, secure partnerships, and capture market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on sales of safety syringes. An analysis of past financial statements is needed.
Future Projections: Future projections are based on analyst estimates, which are not readily available given its market cap and coverage. A discounted cashflow model might be the best means of future assessment
Recent Initiatives: Recent initiatives should be extracted from press releases, investor presentations, and company filings. This might include product launches, partnerships, or acquisitions.
Summary
Sharps Technology is a small company in a competitive medical device market. While its safety syringe technology offers a potential advantage, the company faces significant challenges from larger competitors and financial constraints. Success hinges on effectively scaling operations, securing partnerships, and achieving market penetration while mitigating risk. The warrant's value is entirely dependent on the performance of the underlying common stock.
Similar Companies
- BDX
- SMTH
- TRMO
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sharps Technology Inc. Warrant
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2022-04-14 | CEO & Director Mr. Robert M. Hayes | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 57 | Website https://sharpstechnology.com |
Full time employees 57 | Website https://sharpstechnology.com | ||
Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.